Facebook
Britain's News Portal
Around The Clock
BREAKING
Loading latest headlines…

Chemed Corp shares hit 52-week high amid steady US healthcare demand

Chemed Corporation reached a 52-week high of $512.92 on US markets, driven by resilient hospice and plumbing services revenue. The move highlights ongoing investor confidence in defensive healthcare stocks despite broader economic uncertainty.

  • Chemed Corp hit a 52-week high of $512.92 on 20 July 2026.
  • The company operates VITAS Healthcare, a leading US hospice provider, and Roto-Rooter plumbing services.
  • UK investors with US equity exposure may see gains in defensive healthcare holdings.
  • Analysts cite steady demand for end-of-life care and essential home services as key drivers.
  • The broader healthcare sector remains a safe haven amid interest rate uncertainty.

Chemed Corporation, the US-based provider of hospice care and plumbing services, saw its shares climb to a 52-week high of $512.92 during trading on Monday, 20 July 2026. The stock has risen steadily over the past year, reflecting strong operational performance from its two main subsidiaries: VITAS Healthcare and Roto-Rooter.

Chemed's share price gain comes as investors continue to favour defensive sectors with predictable revenue streams. VITAS Healthcare, which accounts for the bulk of Chemed's revenue, benefits from the demographic tailwind of an ageing US population requiring end-of-life care. Meanwhile, Roto-Rooter provides a counter-cyclical revenue base through essential plumbing and drain cleaning services that remain in demand regardless of economic conditions.

For UK investors holding US equities through pension funds or direct portfolios, Chemed's performance underscores the appeal of defensive healthcare names. The S&P 500 healthcare sector has outperformed the broader index year-to-date, with sub-sectors such as hospice and home health services seeing particular interest. Analysts at Jefferies recently noted that Chemed's diversified business model offers a rare combination of growth and stability, though they cautioned that regulatory changes to Medicare reimbursement rates could pose a risk.

The company reported its most recent quarterly earnings in late April 2026, showing a 7% year-on-year revenue increase to $602m, driven by higher patient admissions at VITAS and a rebound in Roto-Rooter's commercial segment. Operating margins improved slightly, helped by cost controls and favourable labour market conditions in the US.

From a UK perspective, the performance of Chemed and similar US healthcare stocks matters because many British pension funds and investment trusts hold significant allocations to American equities. The FTSE 100, by contrast, has lagged its US counterparts this year, partly due to a stronger pound and slower domestic economic growth. Investors seeking yield and resilience have increasingly looked across the Atlantic, with healthcare and utilities providing relative safety.

Why this matters: UK investors with exposure to US equities, particularly via pension funds or global income funds, are affected by the performance of defensive stocks like Chemed. The stock's 52-week high signals ongoing demand for recession-resistant sectors.

What this means for you: What this means for you: If your pension or investment portfolio holds US healthcare stocks, Chemed's rise reflects broader demand for defensive assets. Keep an eye on upcoming earnings and US healthcare policy changes that could affect valuations.

Related Articles

Get the news that matters.

Join thousands of readers getting the best of British news straight to their inbox.